Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon.
To describe the presence of protease inhibitor (PI) resistance-associated mutations and subtype distribution in drug-naive villagers of six provinces of Cameroon, we sequenced the protease (PR) gene (297 bp) of 128 viruses. Secondary PI resistance-associated mutations were identified at five sites: L10I/V (16%), K20R (8%), M36I (98%), L63P (13%), and V77I (6%). No primary mutation in the PR was identified. Of the 128 specimens analyzed, subtypes A (11%), C(2%), D (6%), F2 (3%), G (6%), H (0.8%), J (6%), and CRF02_AG (60%) were identified. The mutations identified were not characteristic to any particular subtype. The absence of primary mutations, in addition to the few secondary mutations, gives good perspectives for PI treatment interventions in these rural areas.
Department of Microbiology, New York University School of Medicine, New York, New York 10010, USA.
Frank A J
FA
Konings
Ping
P
Zhong
Moise
M
Agwara
Lucy
L
Agyingi
Leopold
L
Zekeng
Jacqueline M
JM
Achkar
Leonard
L
Ewane
Saa
Emmanuel
E
Afane Ze
Thompson
T
Kinge
Phillipe N
PN
Nyambi
D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002163:Cameroon / Q000453:epidemiology; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015497:HIV-1 / Q000145:classification / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009154:Mutation; D012424:Rural Population; D017422:Sequence Analysis, DNA
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D016333:HIV Protease